Key insights
- Goldman Sachs initiated BrightSpring Health Services (BTSG) with a Buy rating and a $71 target, citing accelerating business momentum and strong revenue growth. The firm highlights BTSG's integrated model, particularly its Pharmacy Solutions segment, as a key driver for future earnings. The company's focus on lower-cost care settings and disciplined M&A strategy supports a premium growth outlook, suggesting a positive, albeit moderate, influence on the broader healthcare sector and potentially related equities.
Investing.com - Goldman Sachs initiated coverage on BrightSpring Health Services (NASDAQ:BTSG) with a Buy rating and a price target of $71.00. The stock currently trades at $57.40, up 53% year-to-date, with analyst consensus showing a Strong Buy rating.
The firm said BrightSpring is showing accelerating business momentum. According to InvestingPro data, 10 analysts have revised their earnings upwards for the upcoming period, while the company posted 28% revenue growth over the last twelve months. Its scaled home- and community-based clinical services further align toward lower-cost care settings, coordinated management of complex patients, and tighter integration between specialty and infusion services, clinical oversight, and post acute delivery.
Goldman Sachs said the economic center of gravity of BrightSpring’s business model is Pharmacy Solutions, particularly Specialty and Infusion, which drive most of the revenue growth and earnings power. The surrounding Provider platform, including Home Health, Hospice and RehabCare, adds strategic depth by broadening referral capture, extending the patient relationship, and improving the company’s relevance to payers and providers as more care moves into preferred settings.
The firm views BrightSpring as a leading specialty- and infusion-led growth platform strengthened by a differentiated home and community-based clinical layer. BrightSpring’s integrated model broadens referral capture, more tightly links pharmacy and provider capabilities, and creates a more relevant platform for managing high-acuity patients outside institutional settings.
Goldman Sachs said a track record of disciplined, small-scale, accretive mergers and acquisitions provides a repeatable way to add density and capability without changing the character of the story. That combination supports a premium growth framework rather than a conventional post-acute or provider multiple, the firm said. While InvestingPro analysis suggests the stock appears overvalued relative to its Fair Value, the platform’s comprehensive Pro Research Report—available for BTSG and 1,400+ US equities—offers deeper insights into the company’s growth trajectory and valuation dynamics.
In other recent news, BrightSpring Health Services announced a secondary offering by certain stockholders, involving 15 million shares priced at $58.75 each. The selling stockholders include an affiliate of Kohlberg Kravis Roberts & Co. L.P. and members of management. BrightSpring itself is not selling any shares and will not benefit financially from this offering. Additionally, Morgan Stanley has raised its price target for BrightSpring Health Services to $71, maintaining an Overweight rating, citing an increased target multiple based on projected 2027 EBITDA. BMO Capital also raised its price target to $70, with an Outperform rating, highlighting the role of generic drug conversions in driving EBITDA growth for the company’s Pharmacy segment. These developments reflect recent strategic moves and market evaluations concerning BrightSpring Health Services.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.